Bank Of New York Mellon Corp Revance Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

$538 Trillion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $5.73 Million - $9.59 Million	312,695 New	312,695 $5.77 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $719,337 - $1.43 Million	50,198 Added 19.38%	309,162 $8.35 Million
Q2 2022 Aug 15, 2022	SELL	$11.52 - $20.4 $179,424 - $317,730	-15,575 Reduced 5.67%	258,964 $3.58 Million
Q1 2022 May 11, 2022	SELL	$12.36 - $20.31 $21,073 - $34,628	-1,705 Reduced 0.62%	274,539 $5.35 Million
Q4 2021 Feb 11, 2022	BUY	$12.46 - $27.87 $70,909 - $158,608	5,691 Added 2.1%	276,244 $4.51 Million
Q3 2021 Nov 12, 2021	BUY	$25.78 - $33.21 $509,799 - $656,727	19,775 Added 7.89%	270,553 $7.54 Million
Q2 2021 Aug 11, 2021	SELL	$26.8 - $31.84 $3.37 Million - $4.01 Million	-125,820 Reduced 33.41%	250,778 $7.43 Million
Q1 2021 May 13, 2021	BUY	$24.03 - $29.97 $448,784 - $559,719	18,676 Added 5.22%	376,598 $10.5 Million
Q4 2020 Feb 09, 2021	BUY	$23.41 - $28.34 $1.04 Million - $1.26 Million	44,618 Added 14.24%	357,922 $10.1 Million
Q3 2020 Nov 12, 2020	BUY	$23.23 - $34.3 $788,263 - $1.16 Million	33,933 Added 12.15%	313,304 $7.88 Million
Q2 2020 Aug 12, 2020	BUY	$12.6 - $26.55 $220,663 - $464,970	17,513 Added 6.69%	279,371 $6.82 Million
Q1 2020 May 06, 2020	SELL	$12.46 - $27.81 $822,434 - $1.84 Million	-66,006 Reduced 20.13%	261,858 $3.88 Million
Q4 2019 Feb 14, 2020	SELL	$11.66 - $20.15 $8.71 Million - $15 Million	-746,842 Reduced 69.49%	327,864 $5.32 Million
Q3 2019 Nov 07, 2019	SELL	$10.22 - $14.5 $12.1 Million - $17.1 Million	-1,179,091 Reduced 52.32%	1,074,706 $14 Million
Q2 2019 Aug 12, 2019	SELL	$10.67 - $15.49 $416,001 - $603,924	-38,988 Reduced 1.7%	2,253,797 $29.2 Million
Q1 2019 May 14, 2019	SELL	$15.4 - $20.39 $3.84 Million - $5.09 Million	-249,457 Reduced 9.81%	2,292,785 $36.1 Million
Q4 2018 Feb 11, 2019	BUY	$18.06 - $24.96 $1.4 Million - $1.94 Million	77,625 Added 3.15%	2,542,242 $51.2 Million
Q3 2018 Nov 09, 2018	BUY	$23.55 - $30.1 $12.2 Million - $15.7 Million	519,938 Added 26.74%	2,464,617 $0
Q2 2018 Aug 06, 2018	SELL	$27.45 - $33.35 $1.88 Million - $2.29 Million	-68,553 Reduced 3.41%	1,944,679 $53.4 Million
Q1 2018 May 15, 2018	SELL	$29.15 - $37.4 $3.83 Million - $4.92 Million	-131,437 Reduced 6.13%	2,013,232 $62 Million
Q4 2017 Feb 09, 2018	BUY	$24.55 - $36.3 $52.7 Million - $77.9 Million	2,144,669	2,144,669 $76.7 Million

Others Institutions Holding RVNC

# of Institutions

234

Shares Held

82.8M

Call Options Held

680K

Put Options Held

896K

Black Rock Inc. New York, NY

8.57M
Shares

$22 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

5.73M
Shares

$14.7 Million
0.0% of portfolio
Franklin Resources Inc San Mateo, CA

4.78M
Shares

$12.3 Million
0.0% of portfolio
Fil LTD Hamilton, D0

4.19M
Shares

$10.8 Million
0.01% of portfolio
Alpine Associates Management Inc. Englewood Cliffs, NJ

4.16M
Shares

$10.7 Million
0.49% of portfolio

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account